Clinical trial
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III…
NCT00003647 · Vical, Industry · Completed
Key facts
| NCT number | NCT00003647 |
|---|---|
| Title | Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | Phase III Randomized Study of Dacarbazine With or Without Allovectin-7 in Patients With Metastatic Melanoma |
| Lead sponsor | Vical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma |
| Intervention type | Drug |
| Interventions | allovectin-7, allovectin-7/dacarbazine, dacarbazine |
| Start date | Jul 1, 1998 |
| Completion | Sep 1, 2002 |
| First posted | Mar 23, 2004 |
| Last update posted | Jul 25, 2008 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: